206 related articles for article (PubMed ID: 17957805)
1. Molecular diagnosis and monitoring in the clinical management of patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors.
Ou J; Vergilio JA; Bagg A
Am J Hematol; 2008 Apr; 83(4):296-302. PubMed ID: 17957805
[TBL] [Abstract][Full Text] [Related]
2. Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management.
Martinelli G; Iacobucci I; Soverini S; Cilloni D; Saglio G; Pane F; Baccarani M
Hematol Oncol; 2006 Dec; 24(4):196-204. PubMed ID: 16988930
[TBL] [Abstract][Full Text] [Related]
3. Hematological and molecular response evaluation of CML patients on imatinib.
Gupta A; Prasad K
J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
[TBL] [Abstract][Full Text] [Related]
4. Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation.
Tanaka R; Kimura S
Expert Rev Anticancer Ther; 2008 Sep; 8(9):1387-98. PubMed ID: 18759691
[TBL] [Abstract][Full Text] [Related]
5. Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia.
Hughes T; Branford S
Blood Rev; 2006 Jan; 20(1):29-41. PubMed ID: 16426942
[TBL] [Abstract][Full Text] [Related]
6. Sustained clinical remission despite suboptimal molecular response to imatinib in e1a2 BCR-ABL chronic myeloid leukemia.
Langabeer SE; Crampe M; Haslam K; Kelly J; Cahill MR
Leuk Res; 2010 Jul; 34(7):e176-7. PubMed ID: 20153526
[No Abstract] [Full Text] [Related]
7. [Monitoring of minimal residual disease in patients with chronic myeloleukemia: clinical value of real-time polymerase chain reaction].
Chelysheva EIu; Turkina AG; Misiurin AV; Aksenova EV; Domracheva EV; Zakharova AV; Khoroshko ND
Ter Arkh; 2007; 79(4):49-53. PubMed ID: 17564019
[TBL] [Abstract][Full Text] [Related]
8. Imatinib mesylate, a selective inhibitor of BCR-ABL, in chronic myeloid leukemia.
Carella AM
Expert Rev Anticancer Ther; 2007 Mar; 7(3):249-51. PubMed ID: 17338645
[No Abstract] [Full Text] [Related]
9. Molecular diagnosis and monitoring of chronic myelogenous leukemia: BCR-Abl and more.
Cea M; Cagnetta A; Garuti A; Cirmena G; Rocco I; Moran E; Grillo V; Ballestrero A; Patrone F; Nencioni A
J BUON; 2009; 14(4):565-73. PubMed ID: 20148444
[TBL] [Abstract][Full Text] [Related]
10. Quantitative monitoring by polymerase colony assay of known mutations resistant to ABL kinase inhibitors.
Nardi V; Raz T; Cao X; Wu CJ; Stone RM; Cortes J; Deininger MW; Church G; Zhu J; Daley GQ
Oncogene; 2008 Jan; 27(6):775-82. PubMed ID: 17684485
[TBL] [Abstract][Full Text] [Related]
11. [Importance of quantitative evaluation of BCR-ABL transcripts using real-time PCR for effective treatment of chronic myeloid leukemia].
Beránek M; Voglová J; Sýkorová A; Belada D; Bláha M
Cas Lek Cesk; 2006; 145(1):25-9; discussion 29-30. PubMed ID: 16468238
[TBL] [Abstract][Full Text] [Related]
12. Imatinib resistance in CML.
Volpe G; Panuzzo C; Ulisciani S; Cilloni D
Cancer Lett; 2009 Feb; 274(1):1-9. PubMed ID: 18653275
[TBL] [Abstract][Full Text] [Related]
13. Glivec and CML: a lucky date.
Saglio G; Cilloni D; Rancati F; Boano L
J Biol Regul Homeost Agents; 2004; 18(2):246-51. PubMed ID: 15739279
[TBL] [Abstract][Full Text] [Related]
14. Comparison of allele specific oligonucleotide-polymerase chain reaction and direct sequencing for high throughput screening of ABL kinase domain mutations in chronic myeloid leukemia resistant to imatinib.
Kang HY; Hwang JY; Kim SH; Goh HG; Kim M; Kim DW
Haematologica; 2006 May; 91(5):659-62. PubMed ID: 16627254
[TBL] [Abstract][Full Text] [Related]
15. Tyrosine kinase inhibitors for chronic myelogenous leukemia.
Quintás-Cardama A; Kantarjian H; Cortes J
N Engl J Med; 2007 Oct; 357(15):1557; author reply 1557-8. PubMed ID: 17933034
[No Abstract] [Full Text] [Related]
16. Applying the discovery of the Philadelphia chromosome.
Sherbenou DW; Druker BJ
J Clin Invest; 2007 Aug; 117(8):2067-74. PubMed ID: 17671641
[TBL] [Abstract][Full Text] [Related]
17. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
[TBL] [Abstract][Full Text] [Related]
18. Monitoring disease response to tyrosine kinase inhibitor therapy in CML.
Hughes TP; Branford S
Hematology Am Soc Hematol Educ Program; 2009; ():477-87. PubMed ID: 20008233
[TBL] [Abstract][Full Text] [Related]
19. Imatinib mesylate therapy in chronic myeloid leukaemia: the floodgates opened.
Agarwal MB
J Assoc Physicians India; 2007 Feb; 55():99-100. PubMed ID: 17571737
[No Abstract] [Full Text] [Related]
20. Detection of BCR-ABL gene mutations in Philadelphia chromosome positive leukemia patients resistant to STI-571 cancer therapy.
Chien JH; Tang JL; Chen RL; Li CC; Lee CP
Leuk Res; 2008 Nov; 32(11):1724-34. PubMed ID: 18603297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
